2013
The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder
Diniz J, Costa D, Cassab R, Pereira C, Miguel E, Shavitt R. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder. Journal Of Psychopharmacology 2013, 28: 603-611. PMID: 24288238, DOI: 10.1177/0269881113512042.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicAntipsychotic AgentsBody Dysmorphic DisordersBrazilClomipramineComorbidityDrug Therapy, CombinationFemaleFluoxetineHumansMaleObsessive-Compulsive DisorderProspective StudiesQuetiapine FumarateRisk FactorsTreatment OutcomeConceptsBody dysmorphic disorderComorbid body dysmorphic disorderPharmacological trialsDysmorphic disorderAdult obsessive-compulsive disorder (OCD) patientsSequential treatment strategyObsessive-compulsive disorder patientsSequential treatmentFluoxetine monotherapyClinical characteristicsObsessive-compulsive disorderInitial severityTreatment strategiesDisorder patientsTreatment groupsPatientsWorse responseBDD patientsEffects of sexGEE modelTrialsDisordersSequential trialsWeeksType of augmentation
2005
Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder
Fontenelle L, Mendlowicz M, Miguel E, Versiani M. Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder. The World Journal Of Biological Psychiatry 2005, 6: 57-59. PMID: 16097406, DOI: 10.1080/15622970510029740.Peer-Reviewed Original ResearchConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderSRI-resistant obsessive compulsive disorderResistant obsessive-compulsive disorderCombination of citalopramFirst-line treatmentAdequate trialReuptake inhibitorsCompulsive disorderPatientsCitalopramDisordersFuture studiesTrials